Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.72 |
| ▸ | MEN1 | O00255 | 6/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.72 |
| ▸ | MAPT | P10636 | 5/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.72 |
| ▸ | POLB | P06746 | 4/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.72 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.72 |
| ▸ | IDO1 | P14902 | 1/20 | 0.72 |
| ▸ | TDO2 | P48775 | 1/20 | 0.72 |
| ▸ | GFER | P55789 | 1/20 | 0.72 |
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.57 |
| ▸ | CCR6 | P51684 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 6/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2439461 | 1.00 | L3MBTL1 (0.72) | L3MBTL1MEN1KMT2AMAPTMAPK1 | |
| SCHEMBL11475446 | 0.89 | L3MBTL1 (0.68) | L3MBTL1MEN1KMT2AMAPTMAPK1 | |
| SCHEMBL20280358 | 0.89 | L3MBTL1 (0.68) | L3MBTL1MEN1KMT2AMAPTMAPK1 | |
| SCHEMBL30491095 | 0.84 | MAPT (1.00) | L3MBTL1MEN1KMT2AMAPTMAPK1 | |
| SCHEMBL1683189 | 0.84 | MAPT (1.00) | L3MBTL1MEN1KMT2AMAPTMAPK1 | |
| SCHEMBL30875594 | 0.84 | MAPT (1.00) | L3MBTL1MEN1KMT2AMAPTMAPK1 | |
| SCHEMBL1683188 | 0.84 | MAPT (1.00) | L3MBTL1MEN1KMT2AMAPTMAPK1 | |
| SCHEMBL4726180 | 0.78 | L3MBTL1 (0.68) | L3MBTL1MEN1KMT2AMAPTMAPK1 | |
| SCHEMBL4726175 | 0.78 | L3MBTL1 (0.68) | L3MBTL1MEN1KMT2AMAPTMAPK1 | |
| SCHEMBL14595611 | 0.76 | FBP1 (0.46) | L3MBTL1MEN1KMT2AMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2368558-A1 | Azo compounds reducing formation and toxicity of amyloid beta aggregation intermediates | Mdc Max-Delbrück-Centrum Für Molekulare Medizin Berlin - Buch (DE) | 2011-09-28 | — | — | EP | claimed |
| EP-3347001-B1 | AZOPHENOLS AS ERG ONCOGENE INHIBITORS | HENRY M JACKSON FOUND ADVANCEMENT MILITARY MEDICINE INC (US) | 2023-07-26 | — | — | EP | disclosed |
| US-10238639-B2 | Azophenols as ERG oncogene inhibitors | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180169074-A1 | Azophenols as ERG Oncogene Inhibitors | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-8974768-B2 | Azo compounds reducing formation and toxicity of amyloid beta aggregation intermediates | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2015-03-10 | — | — | US | disclosed |
| US-20130078186-A1 | AZO COMPOUNDS REDUCING FORMATION AND TOXICITY OF AMYLOID BETA AGGREGATION INTERMEDIATES | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2013-03-28 | — | — | US | disclosed |
| EP-2549999-A1 | AZO COMPOUNDS REDUCING FORMATION AND TOXICITY OF AMYLOID BETA AGGREGATION INTERMEDIATES | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2013-01-30 | — | — | EP | disclosed |
| WO-2011117305-A1 | AZO COMPOUNDS REDUCING FORMATION AND TOXICITY OF AMYLOID BETA AGGREGATION INTERMEDIATES | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2011-09-29 | — | — | WO | disclosed |
| EP-2368558-A1 | Azo compounds reducing formation and toxicity of amyloid beta aggregation intermediates | Mdc Max-Delbrück-Centrum Für Molekulare Medizin Berlin - Buch (DE) | 2011-09-28 | — | — | EP | disclosed |
| EP-2368558-A1 | Azo compounds reducing formation and toxicity of amyloid beta aggregation intermediates | Mdc Max-Delbrück-Centrum Für Molekulare Medizin Berlin - Buch (DE) | 2011-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180169074-A1 | Azophenols as ERG Oncogene Inhibitors | ERG, ESR1, CBX2 | L3MBTL1 2210/4885MEN1 1297/4885KMT2A 652/4885 |
| US-10238639-B2 | Azophenols as ERG oncogene inhibitors | ERG, ESR1, CBX2 | L3MBTL1 2210/4885MEN1 1297/4885KMT2A 652/4885 |
| US-20130078186-A1 | AZO COMPOUNDS REDUCING FORMATION AND TOXICITY OF AMYLOID BETA AGGREGATION INTERMEDIATES | APP, TTR, CRYAB | L3MBTL1 2143/4885MEN1 2275/4885KMT2A 3942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.